Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today

Aclaris Therapeutics announced preliminary results from a phase 2a clinical trial of ATI-450, an investigational oral MK2 inhibitor, in patients with moderate to severe rheumatoid arthritis. ATI-450 reportedly demonstrated a "marked and sustained reduction" in disease-activity scores in the placebo-controlled study. Dr. David Gordon, Aclaris chief medical officer, said in a press release, "We believe these data support our hypothesis that MK2 inhibition is an important novel target for the treatment of immuno-inflammatory diseases, such as rheumatoid arthritis, and we look forward to progressing ATI-450 to phase 2b."